Literature DB >> 7379449

Effects of aspirin on platelet aggregation as a function of dosage and time.

M J Paccioretti, L H Block.   

Abstract

There are reports on the effects of high doses of aspirin on the alteration of platelet aggregation. In our study single doses of aspirin ranging from 81 to 325 mg were given orally to 7 normal subjects. In vitro measurement of platelet aggregation was carried out as a function of time. Based on our data we conclude that low-dose aspirin (81 mg) inhibits platelet aggregation. Both the rate and extent of platelet aggregation are impaired with low-dose aspirin, but neither the rate nor extent of platelet aggregation depends on the size of the dose. Platelet aggregation inhibition by a single dose of aspirin orally (greater than or equal to 81 mg) may be expected to persist for the life of the platelets affected.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7379449     DOI: 10.1038/clpt.1980.114

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Applicability and significance of salicylate screening in sera of voluntary blood donors: evaluation of two analytical methods.

Authors:  R Sharon; I Frutkoff; G Kidroni; J Menczel
Journal:  J Clin Pathol       Date:  1982-01       Impact factor: 3.411

2.  Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function.

Authors:  L M Ross-Lee; M J Elms; B E Cham; F Bochner; I H Bunce; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Effect of acetylsalicylic acid on plasma thromboxane B2 and platelet aggregation in man.

Authors:  E Nuotto; A Gordin; M K Paasonen; T Metsä-Ketelä; U Lamminsivu
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Plasma salicylate levels and platelet function after acute and chronic administration of slow-release acetylsalicylic acid (Monobeltin).

Authors:  K Rehders; R Simrock; H Spahn; E Mutschler; H K Breddin
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.